Hengrui Pharmaceuticals rose sharply in the afternoon.

Hengrui Medicine soared straight up in the afternoon, with A shares rising more than 7% at one point and Hong Kong shares rising more than 16%. On the news front, Hengrui Medicine announced that the company has reached a global strategic cooperation and licensing agreement with Bristol-Myers Squibb, jointly advancing 13 early-stage projects covering oncology, hematology, and immunology.